Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May 15;48(10):1413-9.
doi: 10.1086/598191.

Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru

Eda Palacios  1 , Rebecca Dallman, Maribel Muñoz, Rocio Hurtado, Katiuska Chalco, Dalia Guerra, Lorena Mestanza, Karim Llaro, Cesar Bonilla, Peter Drobac, Jaime Bayona, Melissa Lygizos, Holly Anger, Sonya Shin
Affiliations

Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru

Eda Palacios et al. Clin Infect Dis. .

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) disproportionately affects young adults, including women of childbearing age; however, treatment of MDR-TB during pregnancy is still controversial. This study looks at the treatment and pregnancy outcomes in a cohort of women who were treated for MDR-TB during pregnancy during a period of 10 years.

Methods: A retrospective case study was performed using a standardized data collection form and data from 3 ranked sources of patient records. All 38 participants were treated during pregnancy with individualized regimens that included second-line TB medications. We examined the frequency of favorable and adverse outcomes with regard to disease and pregnancy.

Results: After completion of MDR-TB treatment, 61% of the women were cured, 13% had died, 13% had defaulted, 5% remained in treatment, and 5% had experienced treatment failure. Four of the women experienced clinical deterioration of TB during pregnancy. Five of the pregnancies terminated in spontaneous abortions, and 1 child was stillborn. Among the living newborns, 3 were born with low birth weight, 1 was born prematurely, and 1 had fetal distress.

Conclusions: The rates of success in treating MDR-TB in our cohort are comparable to those of other MDR-TB treatment programs in Peru. The birth outcomes of our cohort are similar to those among the general Peru population. Therefore, we advocate that a woman should be given the option to continue treatment of MDR-TB rather than terminating pregnancy or discontinuing MDR-TB treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Baseline Resistance to Drugs, N=38
Figure 2
Figure 2
Frequency of Use in Initial MDR-TB Treatment Regimens, N=38
See this image and copyright information in PMC

References

    1. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006 Dec 16;368(9553):2142–54. - PubMed
    1. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004 Feb 7;363(9407):474–81. - PubMed
    1. WHO [Accessed on July 24, 2008];Treatment of Tuberculosis: guidelines for national programmes. 2003 Available from: http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf.
    1. Margono F, Mroueh J, Garely A, White D, Duerr A, Minkoff HL. Resurgence of active tuberculosis among pregnant women. Obstet Gynecol. 1994 Jun;83(6):911–4. - PubMed
    1. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax. 2001 Jun;56(6):494–9. - PMC - PubMed

Publication types

Substances